AKUMS — Akums Drugs and Pharmaceuticals Balance Sheet
0.000.00%
- IN₹87.62bn
- IN₹82.42bn
- IN₹41.18bn
- 86
- 26
- 49
- 56
Annual balance sheet for Akums Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 874 | 1,033 | 1,505 | 2,878 | 6,246 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6,304 | 10,293 | 9,844 | 10,032 | 7,703 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 11,574 | 18,916 | 19,242 | 19,409 | 22,746 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9,006 | 10,439 | 11,925 | 13,772 | 15,498 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 21,669 | 30,690 | 32,665 | 35,164 | 41,134 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,800 | 12,724 | 12,656 | 12,106 | 8,937 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 12,820 | 24,471 | 25,493 | 28,069 | 10,664 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 8,848 | 6,220 | 7,172 | 7,095 | 30,470 |
Total Liabilities & Shareholders' Equity | 21,669 | 30,690 | 32,665 | 35,164 | 41,134 |
Total Common Shares Outstanding |